• HIV-1 Protease Autoprocessing as a Drug Target

  2026-09-24

  The study developed a cell-based AlphaLISA platform to screen for inhibitors of HIV-1 protease autoprocessing, an early maturation step distinct from inhibition of the mature enzyme. The assay met a high-throughput screening quality threshold, distinguished HIV protease inhibitors from other protease inhibitors, and reproduced resistance patterns in mutant precursors, supporting its use in drug discovery and resistance assessment.

• GI 254023X: ADAM10 Inhibitor Workflows

  2026-09-24

  Use GI 254023X to probe ADAM10-dependent Notch1 processing in Jurkat cells and VE-cadherin shedding during endothelial toxin injury. This guide turns its reported potency and model-specific findings into practical, control-rich workflows while distinguishing established observations from optimization suggestions.

• EZ Cap™ Reagent GG in p21 mRNA Research

  2026-09-23

  EZ Cap™ Reagent GG belongs to the mRNA-production stage of a workflow, while therapeutic performance depends on much more than the cap. This article connects RNA-quality decisions with a recent preclinical study of intravesical p21 mRNA–lipid nanoparticles and explains what the evidence does—and does not—establish.

• (S)-(+)-Ibuprofen: COX Inhibitor Workflow

  2026-09-23

  Build cleaner COX inhibition assays with the pharmacologically active ibuprofen enantiomer, from soluble stock preparation through pathway-level readouts. The same compound also supports aquatic toxicology and translational comparisons when exposure, vehicle, and species-specific limitations are handled explicitly.

• Metal-Free Carbon Nanozymes for ALP Detection

  2026-09-22

  Hsieh and colleagues developed a metal-free carbon-dot nanozyme assay that converts alkaline phosphatase hydrolysis of pyrophosphate into a colorimetric turn-on response. Kinetic analysis showed that pyrophosphate inhibits the carbon dots at a site distinct from the catalytic site, supporting sensitive ALP activity measurements while reducing metal-ion-related interference.

• Caffeic Acid Phenethyl Ester (CAPE) NF-κB Workflows

  2026-09-22

  Caffeic Acid Phenethyl Ester (CAPE) is a focused NF-κB pathway probe for separating inflammatory signaling from cell loss, angiogenesis, and invasion phenotypes. This practical guide connects CAPE assay design with the Fyn–Stat3–NF-κB zebrafish neurodegeneration model while distinguishing established evidence from exploratory applications.

• PD 173074: FGFR1 and VEGFR2 Research Guide

  2026-09-21

  PD 173074 is an ATP-competitive FGFR1 and VEGFR2 inhibitor used to study FGFR signaling pathway inhibition, angiogenesis, and cancer research. Its strongest evidence supports biochemical kinase inhibition and preclinical pathway interrogation, not established clinical efficacy.

• Pifithrin-α: Translating p53 Insight into Protection

  2026-09-21

  Pifithrin-α (PFTα) is more than a conventional p53 inhibitor: it is a mechanistic probe for separating p53-driven apoptosis, ferroptosis, and cell-cycle responses. This article connects recent neurotoxicology findings with translational strategies for radiation biology, neuroprotection, and cancer therapy side effect mitigation.

• Oligo (dT) 25 Beads for Immune RNA Insight

  2026-09-20

  Oligo (dT) 25 Beads provide selective polyA tail mRNA capture for clean, adaptable transcript workflows. This article explains how magnetic enrichment can support immune-aging studies while preserving the distinctions between bulk mRNA assays and single-cell RNA sequencing.

• Dextrose (D-glucose) for Reliable Cell Assays

  2026-09-19

  This scenario-based guide explains how Dextrose (D-glucose), SKU A8406, can improve control of glucose-dependent variables in cell viability, proliferation, cytotoxicity, and immunometabolism workflows. It combines practical concentration planning, solution-handling guidance, data interpretation, and evidence from recent tumor hypoxia research.

• Lamotrigine Research Workflows for Ion Channels

  2026-09-18

  Build reproducible Lamotrigine assays for neuronal sodium-channel studies, serotonin pathway experiments, and cardiac electrophysiology. This guide combines solubility-aware dosing with an HPLC-MS-inspired workflow that helps distinguish direct pharmacology from compound handling artifacts.

• WP1066: Contextual Control of JAK2/STAT3

  2026-09-18

  WP1066, a cell-permeable JAK2/STAT3 inhibitor, can reveal whether pathway activity is causally required in cancer and macrophage-centered repair models. This guide connects mechanistic pharmacology with assay design while clarifying why pathway inhibition and activation must not be conflated.

• Bazedoxifene Repurposing for Antimalarial Research

  2026-09-17

  Sudhakar et al. show that bazedoxifene, a selective estrogen receptor modulator used in postmenopausal osteoporosis, inhibits erythrocytic Plasmodium development and disrupts hemozoin formation. The study supports a mechanistically informed repurposing strategy while highlighting parasite stage, host sex, and model selection as important variables for translation.

• Dextrose for Tumor Immunometabolism Workflows

  2026-09-17

  Build controlled glucose gradients, hypoxia models, and immune–tumor co-cultures with Dextrose (D-glucose) as an adjustable metabolic input. This workflow-focused guide connects reagent handling with assay design, troubleshooting, and practical interpretation of nutrient competition in the tumor microenvironment.

• 4-Methoxychalcone-1 in Secretory Cell Research

  2026-09-16

  Explore how 4-Methoxychalcone-1 can be evaluated as an exploratory chemical perturbation in single-cell secretion studies. This article connects compound testing with SEC-seq, showing why secretion measurements and transcriptomic state should be interpreted together.

515 records 1/35 page Next 12345 下5页 Last page